Overview

A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid

Status:
Completed
Trial end date:
2021-04-14
Target enrollment:
Participant gender:
Summary
This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).
Phase:
Phase 2
Details
Lead Sponsor:
Alkahest, Inc.
Treatments:
Mometasone Furoate